HomeInsights52 Week Low Stocks

Glenmark Pharmaceuticals Ltd 52 Week Low

Glenmark Pharmaceuticals Ltd 52 Week Low

stocks purchased

₹ 1.1 Cr

Volume Transacted

(Dec 26, 2024)

stocks purchased

7.2 K

Stocks Traded

(Dec 26, 2024)

Last Updated on: Dec 26, 2024

Image

Glenmark Pharmaceuticals Ltd

NSE: GLENMARK

YEARLOW

₹ 766.65

Last updated on: Dec 24, 2024

Key Highlights

  • The 52 Week Low of Glenmark Pharmaceuticals Ltd is ₹ 766.65 as of 24 Dec 24 .

Company Fundamentals for Glenmark Pharmaceuticals Ltd

No data available

Market Price of Glenmark Pharmaceuticals Ltd

1M

1Y

3Y

5Y

Monitoring Glenmark Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
24 Dec 20241536.15
23 Dec 20241549.95
20 Dec 20241542.35
19 Dec 20241540
18 Dec 20241524.2
17 Dec 20241512.6
16 Dec 20241551.4
13 Dec 20241517.2
12 Dec 20241534.5
11 Dec 20241526.1

Asset Value vs Market Value of Glenmark Pharmaceuticals Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Historical Revenue of Glenmark Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Net Profit of Glenmark Pharmaceuticals Ltd

No data available

* All values are in crore

Glenmark Pharmaceuticals Ltd News Hub

News

Glenmark Pharmaceuticals Inc. USA launches Lacosamide Oral Solution

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Lacosamide Oral Solu...

Read more

16 Dec 2024 09:06

News

Glenmark Pharma arm launches seizure drug in US

The newly launched drug is bioequivalent and therapeutically equivalent to the reference l...

Read more

16 Dec 2024 09:41

News

Glenmark Pharmaceuticals Ltd up for third straight session

Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quotin...

Read more

03 Dec 2024 13:06

News

Glenmark Pharma launches Travoprost Ophthalmic Solution USP

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Travoprost Ophthalmi...

Read more

27 Nov 2024 09:12

News

Glenmark Pharma arm launches Travoprost Ophthalmic Solution in U.S market

Travoprost ophthalmic is used to treat glaucoma (a condition in which increased pressure i...

Read more

27 Nov 2024 09:59

News

Glenmark Pharmaceuticals Ltd eases for fifth straight session

Glenmark Pharmaceuticals Ltd dropped for a fifth straight session today. The stock is quot...

Read more

18 Nov 2024 13:35

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for 52 Week Low of Glenmark Pharmaceuticals Ltd

Why is it important to track the 52-week low of Glenmark Pharmaceuticals Ltd stocks?

Investors should monitor the 52-week low of Glenmark Pharmaceuticals Ltd stocks regularly to stay informed about significant price changes and assess the stock's performance over time. Frequent monitoring will help traders identify trends and make timely decisions.

What factors can lead to Glenmark Pharmaceuticals Ltd stocks hitting a 52-week low?

Factors leading to Glenmark Pharmaceuticals Ltd stocks hitting a 52-week low may include poor fiscal results, negative industry trends, macroeconomic issues, or management changes. Other factors such as market volatility and broader economic downturns can also contribute to a 52-week low.

Should investors buy Glenmark Pharmaceuticals Ltd stocks when they hit a 52-week low?

Buying Glenmark Pharmaceuticals Ltd stocks at a 52-week low can offer a potential bargain, however, it is crucial to evaluate the reasons behind the stock price drop and ensure there is no underlying fundamental issue. Investors should consider the company's long-term prospects before making a buying decision.

How often should investors monitor the 52-week low of Glenmark Pharmaceuticals Ltd stocks?

Investors should monitor the 52-week low of Glenmark Pharmaceuticals Ltd stocks regularly to stay informed about significant price changes and assess the stock's performance over time, which will help them identify trends and make timely decisions.

How can an investor assess the risk of buying Glenmark Pharmaceuticals Ltd stock at their 52-week low?

An investor can analyze the reasons for the Glenmark Pharmaceuticals Ltd stock price drop, evaluate the company’s fundamentals, and consider market conditions. Investors should also review the stock’s historical performance and any potential recovery indicators.

Should investors consider the overall market trend when evaluating Glenmark Pharmaceuticals Ltd stocks at their 52-week low?

Certainly, considering the overall market trend when evaluating Glenmark Pharmaceuticals Ltd stocks at their 52-week low is significant as it provides context for the stock’s performance and potential future movements. A declining market trend may influence Glenmark Pharmaceuticals Ltd stock performance, impacting the timing and potential of the investment.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Demat Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Demat Account
Verify your phone
+91
*By signing up you agree to our terms & conditions